HP
SAGE

Harbourvest Partners’s Sage Therapeutics SAGE Stock Holding History

Harbourvest Partners’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-11,319
Closed -$705K – 25
2017
Q3 		$705K Buy
+11,319
New +$889K 0.47% 13
2017
Q1 		– Sell
-23,168
Closed -$1.18M – 20
2016
Q4 		$1.18M Sell
23,168
-50,000
-68% -$2.36M 0.71% 9
2016
Q3 		$3.37M Sell
73,168
-31,400
-30% -$1.28M 1.86% 5
2016
Q2 		$3.15M Hold
104,568
– – 1.52% 5
2016
Q1 		$3.35M Hold
104,568
– – 1.43% 6
2015
Q4 		$6.1M Sell
104,568
-59,251
-36% -$2.94M 2.23% 5
2015
Q3 		$6.93M Buy
163,819
+102,639
+168% +$6.33M 3.06% 6
2015
Q2 		$4.47M Buy
+61,180
New +$3.93M 2.05% 5

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Harbourvest Partners's SAGE Position: Q4 2017 in Review

Harbourvest Partners sold out of Sage Therapeutics (SAGE) in Q4 2017, closing a stake of 11,319 shares — an estimated $705K sold.

Harbourvest Partners first reported a position in SAGE in Q2 2015 and held it in 8 quarters. The position peaked at $6.93M in Q3 2015. 224 funds tracked by Wall St. Rank hold SAGE as of Q4 2017.

  • Harbourvest Partners reported no remaining Sage Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Harbourvest Partners sold 11,319 Sage Therapeutics shares in Q4 2017, an estimated $705K.
  • Harbourvest Partners first reported a position in Sage Therapeutics in Q2 2015 and held it in 8 quarters.
  • Harbourvest Partners's Sage Therapeutics position peaked at $6.93M in Q3 2015.
  • 224 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2017.

Based on Harbourvest Partners's 13F filing for Q4 2017, filed 14 Feb 2018.